

IND SAFETY REPORT: INITIAL WRITTEN REPORT**TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**1. IND NUMBER
79212. AGENT NAME
Bevacizumab (rhuMAb VEGF)3. DATE
January 13, 20104. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute5. REPORTER'S NAME, TITLE, AND INSTITUTION
Kevin C. Conlon, MD-Senior Investigator for Investigational Therapeutics 3, CTEP, DCTD, NCI6. PHONE NUMBER
301-496-11967. FAX NUMBER
301-402-04288. PROTOCOL NUMBER (AE #)
E1505 (AE # 1901777)9. PATIENT IDENTIFICATION
1553310. AGE
6111. SEX
Male

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 61-year-old male with non-small cell lung cancer who experienced a grade 4 hemoptysis while on a phase 3 study using the investigational agent bevacizumab in conjunction with docetaxel and cisplatin. He began his first course of treatment on December 2, 2009, and received the last dose of bevacizumab on December 2, 2009 (Cycle 1, Day 1). Docetaxel and cisplatin were also last given December 2, 2009. On December 18, 2009 (Cycle 1, Day 17), the patient developed sudden and severe hemoptysis. He reported to the ER where he had another episode of hemoptysis and was promptly admitted. A chest CT scan was done and showed results which were unchanged from the baseline. Laboratory findings were unremarkable. On December 21, 2009, the patient had a bronchoscopy but became pulseless during the procedure and was revived with CPR. The results showed no definite site of bleeding. He was later taken for angiography, and a bronchial artery embolization was done to curtail the bleeding; but the patient had suffered anoxic encephalopathy during the earlier resuscitative efforts and remains in a coma. Additional information has been requested from the hospital. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE **Cycle = 3 weeks****Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 (Cycles 1-4);****Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 every 3 weeks for up to 1 year (after 4 Cycles)**14. DATES OF TREATMENT **The patient started the investigational therapy on December 2, 2009. This was the first and the only dose of bevacizumab that was administered.**15. ACCRUAL AND IND EXPERIENCE **Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 24655. Pulmonary hemorrhage is an expected adverse event for bevacizumab.**16. COMMENTS **The following was also administered:****Cycle 1, Day 1: Cisplatin 75 mg/m² IV over 60 minutes on Day 1 (last administered on December 2, 2009)****Cycle 1, Day 1: Docetaxel 75mg/m² IV over 60 minutes on Day 1 (last administered on December 2, 2009)****AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).****DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**